Eran Ophir Biography and Net Worth

President and CEO of Compugen

Eran became President and Chief Executive Officer of Compugen and joined Compugen’s Board of Directors in September 2025. Prior to his current position, Eran served in various managerial and executive roles at Compugen for nearly a decade. In his most recent position as Chief Scientific Officer, he led research and discovery efforts and played a central role in building the Company’s innovative immuno-oncology pipeline and corporate strategy. Eran joined Compugen in 2015 as a senior scientist and has since held various positions in Compugen with increasing responsibilities including appointment to the management team in March 2020. Eran received a B.Sc. in Bioinformatics from Tel Aviv University, a Ph.D. in Biology from the Weizmann Institute of Science and served as a Postdoctoral Research Fellow at the Ludwig Institute for Cancer Research, Switzerland.

What is Eran Ophir's net worth?: The estimated net worth of Eran Ophir is at least $26.85 thousand as of April 24th, 2026. Mr. Ophir owns 11,375 shares of Compugen stock worth more than $26,845 as of July 16th. This net worth estimate does not reflect any other investments that Mr. Ophir may own. Learn More about Eran Ophir's net worth.
How do I contact Eran Ophir?: The corporate mailing address for Mr. Ophir and other Compugen executives is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. Compugen can also be reached via phone at (723) 765-8585 and via email at [email protected]. Learn More on Eran Ophir's contact information.
Has Eran Ophir been buying or selling shares of Compugen?: Eran Ophir has not been actively trading shares of Compugen within the last three months. Most recently, Eran Ophir sold 5,000 shares of the business's stock in a transaction on Friday, April 24th. The shares were sold at an average price of $3.20, for a transaction totalling $16,000.00. Following the completion of the sale, the chief executive officer now directly owns 11,375 shares of the company's stock, valued at $36,400. Learn More on Eran Ophir's trading history.
Are insiders buying or selling shares of Compugen?: In the last year, insiders at the biotechnology company sold shares 9 times. They sold a total of 34,000 shares worth more than $88,476.25. The most recent insider tranaction occured on July, 9th when SVP Zurit Levine sold 1,875 shares worth more than $4,687.50. Insiders at Compugen own 9.5% of the company. Learn More about insider trades at Compugen.
Information on this page was last updated on 7/9/2026.

Eran Ophir Insider Trading History at Compugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/24/2026	Sell	5,000	$3.20	$16,000.00	11,375
4/14/2026	Sell	5,000	$2.90	$14,500.00	11,375
4/1/2026	Sell	5,625	$2.21	$12,431.25	11,375

Eran Ophir Buying and Selling Activity at Compugen

Compugen Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Today's Range

Now: $2.37

$2.35

$2.43

50 Day Range

MA: $2.38

$1.96

$3.03

2 Week Range

Now: $2.37

$1.29

$3.23

Volume

50,637 shs

Average Volume

423,474 shs

Market Capitalization

$223.62 million

P/E Ratio

6.39

Dividend Yield

N/A

Beta

2.76